- Home
- ADI vs BMY Comparison
ADI vs BMY Comparison
Compare ADI & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADI
- BMY
- Stock Information
- Founded
- ADI 1965
- BMY 1887
- Country
- ADI United States
- BMY United States
- Employees
- ADI N/A
- BMY N/A
- Industry
- ADI Semiconductors
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- ADI Technology
- BMY Health Care
- Exchange
- ADI Nasdaq
- BMY Nasdaq
- Market Cap
- ADI 115.2B
- BMY 95.0B
- IPO Year
- ADI 1972
- BMY N/A
- Fundamental
- Price
- ADI $234.39
- BMY $46.24
- Analyst Decision
- ADI Buy
- BMY Hold
- Analyst Count
- ADI 22
- BMY 11
- Target Price
- ADI $270.00
- BMY $55.64
- AVG Volume (30 Days)
- ADI 3.5M
- BMY 16.4M
- Earning Date
- ADI 11-25-2025
- BMY 10-30-2025
- Dividend Yield
- ADI 1.70%
- BMY 5.36%
- EPS Growth
- ADI 18.69
- BMY N/A
- EPS
- ADI 3.93
- BMY 2.97
- Revenue
- ADI $10,386,795,000.00
- BMY $48,034,000,000.00
- Revenue This Year
- ADI $17.28
- BMY N/A
- Revenue Next Year
- ADI $13.28
- BMY N/A
- P/E Ratio
- ADI $59.12
- BMY $15.57
- Revenue Growth
- ADI 7.08
- BMY 1.26
- 52 Week Low
- ADI $158.65
- BMY $42.52
- 52 Week High
- ADI $258.13
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- ADI 48.56
- BMY 50.94
- Support Level
- ADI $224.25
- BMY $45.27
- Resistance Level
- ADI $235.28
- BMY $49.99
- Average True Range (ATR)
- ADI 6.46
- BMY 1.19
- MACD
- ADI -0.19
- BMY -0.13
- Stochastic Oscillator
- ADI 53.75
- BMY 20.53
About ADI Analog Devices Inc.
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.